While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
Website External link for Digital Investments and Strategies Industry Investment Banking Company size 2-10 employees Headquarters San Francisco, California Type Privately Held Founded 2000 Specialties investment banking, cross border deals, Fund Raising, Growth Capital, M&A, Corporate Venture, Corporate development, corporate finance, Saudi Arabia, Infrastructure, Energy, F&B, AI, and Secondaries Locations Primary Get directions 814 Mission St 6th floor San Francisco, California 94103, US Get directions Av de Mari Fortuny 87 3rd Floor Reus, Catalonia 43203, ES
You have no idea if the product you're buying is pure, under-dosed, or even contains the correct substance at all
This stability allows researchers to investigate both oral and parenteral administration routes in animal-model designs, an unusual flexibility among peptide research compounds
